Evidence map›Paper›PMID 41356711›Full record

ArticleRSC advances2025

Design, synthesis and anti-cervical cancer activity of aroylpyrrole-based derivatives as potent histone deacetylase 6 inhibitors.

Xingjie Wang, Lixuan Du, Yaxin Xue, Yitong Su, Xuetao Yuan, Shuting Yang, Weiyi Su, Wenli Gou, Xin Chen, Lu Zong

Abstract read
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xingjie WangDepartment of General Surgery, The First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi 710061 P. R. China.
Lixuan DuDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi 710061 P. R. China.
Yaxin XueDepartment of Obstetrics & Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi 710061 P. R. China 13572870556@126.com catherazong@163.com +86-029-85323338.
Yitong SuDepartment of Obstetrics & Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi 710061 P. R. China 13572870556@126.com catherazong@163.com +86-029-85323338.
Xuetao YuanDepartment of General Surgery, The First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi 710061 P. R. China.
Shuting YangDepartment of General Surgery, The First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi 710061 P. R. China.
Weiyi SuDepartment of Obstetrics & Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi 710061 P. R. China 13572870556@126.com catherazong@163.com +86-029-85323338.
Wenli GouDepartment of Obstetrics & Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi 710061 P. R. China 13572870556@126.com catherazong@163.com +86-029-85323338.
Xin ChenShaanxi Key Labotory of Natural Products & Chemical Biology, College of Chemistry & Pharmacy, Northwest A & F University Yangling 712100 P. R. China chenxin1888@nwsuaf.edu.cn +87-029-87092335.ORCID https://orcid.org/0000-0001-8623-7655
Lu ZongDepartment of Obstetrics & Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi 710061 P. R. China 13572870556@126.com catherazong@163.com +86-029-85323338.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancers, such as cervical carcinoma, are one of the most significant diseases affecting human health and histone deacetylases (HDACs) are striking targets in current antitumor drug development. Compared to pan-HDAC inhibitors with potential toxicity, the development of selective HDAC6 inhibitors (sHDAC6is) is a major research focus. In this study, a series of derivatives bearing an aroylpyrrole core were designed and synthesized using a scaffold-hopping strategy. Among these, the best compound 4-benzoyl-1-(4-fluorobenzyl)-

Identifiers

PMID41356711
PMCPMC12679430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.